Navigation Links
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
Date:11/26/2008

SAN DIEGO, Nov. 26 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not demonstrate an appreciable difference between patients treated with CERE-120 versus those in the control group. Both groups showed an approximate 7 point improvement in the protocol-defined primary endpoint (Unified Parkinson's Disease Rating Scale- motor off score at 12 months), relative to a mean at baseline of approximately 39 points. Both groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. CERE-120 appeared to be safe and well tolerated.

"On behalf of everyone at Ceregene, I would like to personally express my gratitude to all the patients, physicians and staff who participated in this study. We share their disappointment. We also offer our heartfelt appreciation to the many talented and dedicated employees at Ceregene who continue to work extremely hard on this and Ceregene's other programs," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "We continue to believe in the multiple opportunities in our pipeline that target a range of serious neurodegenerative and ocular diseases."

"The medical research community has for several decades attempted to use the unique healing properties of neurotrophic factors to treat serious neurodegenerative diseases, and Ceregene's use of gene therapy as an essential enabling technology to translate this idea into an effective human therapeutic has consistently generated strong empirical support," stated Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer. "Thus, we are stunned by the results of this trial and will continue to analyze the data in order to gain greater insight into the factors that may have contr
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Ceregene Announces Two Key Additions to Leadership Team
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... July 23 eResearchTechnology,Inc. (eRT or the Company), ... ECG and eClinical technology, ePRO and other services ... today the appointment of Mr. Keith D. Schneck ... July 28th, 2008., Mr. Schneck joins eRT ...
... Plans for Regaining Compliance - - NASDAQ Hearing Panel ... ... Other NASDAQ Capital Market Initial Listing ... TUSTIN, Calif., July 23 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ...
... July 23 Best Practices, LLC is a,research, ... in the,field of best practice benchmarking focused on ... Best Practices, LLC is,conducting business function specific Webinars ... Web-Conferences Scheduled in July 2008, Best Practices, ...
Cached Biology Technology:eResearchTechnology Names New Chief Financial Officer 2eResearchTechnology Names New Chief Financial Officer 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 2Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 4Web-Conferences by Best Practices, LLC for July 2008 2
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... that devastate honeybees in Europe, Asia and the United ... appear to be impacting native honeybee populations at this ... invasive pests include including Nosema microsporidia and ... to be resilient to these invasive pests, which suggests ... in Europe, Asia and the United States currently are ...
(Date:4/17/2014)... Cell Press journal Current Biology on April ... sex lives. The Brazilian insects, which represent four distinct ... are the first example of an animal with sex-reversed ... in several different animals, Neotrogla is the ... reversed," says Kazunori Yoshizawa from Hokkaido University in Japan. ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3In sex-reversed cave insects, females have the penises 2
... Medicine of Yeshiva University have received a $2 million ... "microenvironments" --where tumors interact with surrounding tissues, cells and ... cells to invade other areas of the body in ... new NCI grant, Dr. John Condeelis, co-chair of anatomy ...
... stem cells with a surprising capacity for repair, researchers ... Cell, published by Cell Press. The novel insight into ... clinical implications for the treatment of brain damage, according ... whose brains were severely damaged by loss of the ...
... of fixing nitrogen at a surprisingly hot 92 degrees ... of organisms capable of nitrogen fixation, perhaps even preceding ... on to fix nitrogen. , The genetic analysis ... the notion that the gene needed to produce nitrogenase ...
Cached Biology News:World's smallest cancer detection device 2Neural stem cells lend the brain a surprising capacity for self-repair 2Microbe fixes nitrogen at a blistering 92 C 2Microbe fixes nitrogen at a blistering 92 C 3
...
... Medium is formuatled for the growth ... and Sf21 cells. Grace's Insect Mediu, ... it does not contain lactalbumin hydrosylate, ... transfection. Grace's Insect Medium, Supplemented is ...
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
Biology Products: